Version No: MSDS/Aci-AUS/DP-001 **Effective Date:** 1st July 2020

ACICLOVIR INJECTION, 25 mg/mL, 10 mL, 20 mL and 40 mL

SECTION 1 – PRODUCT AND COMPANY IDENTIFICATION

Product Name: Aciclovir Injection, 25 mg/mL, 10 mL, 20 mL and 40 mL

Intended Use:	Pharmaceutical product used as antiviral		
Details of the Supplier of the Safety Data Sheet			
Manufacturer:	Sponsor:		
Intas Pharmaceuticals Ltd.	Accord Healthcare Pty Ltd		
Plot No. 457, 458	Level 24, 570 Bourke Street,		
Village-Matoda,	Melbourne, VIC, 3000,		
Bavla Road, Ta. Sanand,	Australia		
Dist. Ahmedabad-382 210,			
Gujarat, India			

SECTION 2 – COMPOSITION, INFORMATION ON INGREDIENTS

Hazardous:

Active Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Acyclovir Sodium	69657-51-8	Not listed	Mut. Cat.3;R68	2.5
			Repr. Cat.3;R62 Repr. Cat.3;R63	

Inactive Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Hydrochloric acid	7647-01-0	231-595-7	Press. Gas	**
			Skin Corr.1A (H314)	
			Acute Tox.3 (H331)	
Sodium hydroxide	1310-73-2	215-185-5	C;R35	**
Water for injection	7732-18-5	231-791-2	Not Listed	*

Additional Information:

* Proprietary ** to adjust pH

Ingredient(s) indicated as hazardous have been assessed under

standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

Version No: MSDS/Aci-AUS/DP-001 Effective Date: 1st July 2020

SECTION 3 - HAZARDS IDENTIFICATION

Appearance : Clear, colorless to pale yellow solution.

Signal Word : WARNING

Statement of Hazard : Suspected of damaging fertility or the unborn child.

Suspected of causing genetic defects.

Additional Hazard Information

EU Risk Phrases

Note

Short Term : Not acutely toxic (based on animal data).

Long Term : Repeat-dose studies in animals have shown a potential to

cause adverse effects on testes, the developing fetus

: The most common adverse effects reported with clinical **Known Clinical Effects**

use were diarrhea, nausea, rash, and vomiting. Kidney

dysfunction has been seen during clinical use. Toxic to Reproduction: Category 3 **EU** Indication of danger

Mutagenic: Category 3

EU Hazard Symbols :

: R62 - Possible risk of impaired fertility.

R63 - Possible risk of harm to the unborn child.

R68 - Possible risk of irreversible effects.

Australian Hazard : Hazardous Substance. Non-Dangerous Goods.

: This document has been prepared in accordance with **Classification (NOHSC)**

standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon

the potential for exposure in your workplace.

SECTION 4 - FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Version No: MSDS/Aci-AUS/DP-001 Effective Date: 1st July 2020

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 3 – Hazards Identification and/or Section 11 - Toxicological Information

SECTION 5 - FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

SECTION 6 - ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

SECTION 7 - HANDLING AND STORAGE

General Handling:

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the

Version No: MSDS/Aci-AUS/DP-001 Effective Date: 1st July 2020

> atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Store as directed by product packaging. **Storage Conditions:**

SECTION 8 - EXPOSURE CONTROLS/PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Hvdrochloric Acid:

Italy OEL - TWA

Lithuania OEL - TWA

ACGIH Ceiling Threshold Limit: 2 ppm **Australia PEAK** 5 ppm

 7.5 mg/m^3

Austria OEL - MAKs 5 ppm

 8 mg/m^3

: 5 ppm **Belgium OEL - TWA**

 8 mg/m^3

Bulgaria OEL - TWA : 5 ppm

 8.0 mg/m^3

5 ppm **Cyprus OEL - TWA**

 8 mg/m^3

Czech Republic OEL - TWA 8 mg/m^3

Estonia OEL - TWA 5 ppm

 8 mg/m^3

Germany - TRGS 900 - TWAs : 2 ppm

 3 mg/m^3

Germany (DFG) - MAK : 2 ppm

 3.0 mg/m^3

Greece OEL - TWA 5 ppm

 7 mg/m^3

 \cdot 8 mg/m³ **Hungary OEL - TWA Ireland OEL - TWAs**

: 5 ppm

 8 mg/m^3 : 5 ppm

 8 mg/m^3

Japan - OELs - Ceilings **:** 2 ppm

 3.0 mg/m^3

Latvia OEL - TWA 5 ppm

 8 mg/m^3

: 5 ppm

 8 mg/m^3

Luxembourg OEL - TWA : 5 ppm

 8 mg/m^3

Malta OEL - TWA : 5 ppm

Version No: MSDS/Aci-AUS/DP-001 Effective Date: 1st July 2020

 8 mg/m^3

Netherlands OEL - TWA: 8 mg/m³Poland OEL - TWA: 5 mg/m³Portugal OEL - TWA: 5 ppm

 8 mg/m^3

Romania OEL - TWA : 5 ppm

 8 mg/m^3

Slovakia OEL - TWA : 5 ppm

 8.0 mg/m^3

Slovenia OEL - TWA : 5 ppm

 8 mg/m^3

Spain OEL - TWA : 5 ppm

 7.6 mg/m^3

Switzerland OEL -TWAs : 2 ppm

 3.0 mg/m^3

Vietnam OEL - TWAs : 5 mg/m³

Sodium hydroxide:

ACGIH Ceiling Threshold Limit $: 2 \text{ mg/m}^3$ $: 2 \text{ mg/m}^3$ **Australia PEAK** $: 2 \text{ mg/m}^3$ **Austria OEL – MAKs** Bulgaria OEL – TWA 2.0 mg/m^3 Czech Republic OEL – TWA $: 1 \text{ mg/m}^3$ Estonia OEL – TWA 1 mg/m^3 France OEL - TWA $: 2 \text{ mg/m}^3$ $: 2 \text{ mg/m}^3$ **Greece OEL - TWA Hungary OEL – TWA** \cdot 2 mg/m³ $\cdot 2 \text{ mg/m}^3$ Japan - OELs – Ceilings $: 0.5 \text{ mg/m}^3$ Latvia OEL – TWA $: 2 \text{ mg/m}^3$ **OSHA - Final PELS - TWAs** $: 0.5 \text{ mg/m}^3$ Poland OEL – TWA Slovakia OEL – TWA $: 2 \text{ mg/m}^3$ Slovenia OEL – TWA $: 2 \text{ mg/m}^3$ 1 mg/m^3 **Sweden OEL - TWAs**

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Version No: MSDS/Aci-AUS/DP-001 Effective Date: 1st July 2020

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: Whenever excessive air contamination (dust, mist, vapor) is generated, respiratory protection, with appropriate protection factors, should be used to minimize exposure.

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solution

Color: Clear, colorless to pale yellow

Molecular Formula: Mixture **Molecular Weight:** Mixture

SECTION 10 - STABILITY AND REACTIVITY

Chemical Stability: Stable under normal conditions of use.

Conditions to Avoid: None known.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

SECTION 11 - TOXICOLOGY INFORMATION

General Information: The information included in this section describes the potential

hazards of the individual ingredients.

Acute Toxicity:

Acyclovir Sodium:

Species	Route	End Point	Dose
Rat	Oral	LD 50	> 20 g/kg
Rat	Para-periosteal	LD 50	750 mg/kg
Rat	Intraperitoneal	LD 50	860 mg/kg
Mouse	Oral	LD 50	> 10 g/kg
Mouse	Intravenous	LD 50	400 mg/kg

Sodium hydroxide:

Species	Route	End Point	Dose
Mouse	IP	LD50	40 mg/kg

Version No: MSDS/Aci-AUS/DP-001 Effective Date: 1st July 2020

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization:

Hydrochloric Acid:

Study Type	Severity
Skin Irritation	Severe
Eye Irritation	Severe

Sodium hydroxide:

Study Type	Species	Severity
Eye Irritation	Rabbit	Severe
Skin Irritation	Rabbit	Severe

Repeated Dose Toxicity:

Acyclovir Sodium:

Duration	Species	Route	Dose	End Point	Target Organ
1 Month(s)	Rat	Intraperitoneal	320 mg/kg/day	LOAEL	Male reproductive system
1 Month(s)	Dog	Intravenous	100-200 mg/kg/day	LOAEL	Male reproductive system
1 Month(s)	Dog	Intravenous	50 mg/kg/day	NOAEL	Male reproductive system
6 Month(s)	Rat	Intraperitoneal	80 mg/kg/day	LOAEL	Male reproductive system
1 Year (s)	Dog	Intravenous	60 mg/kg/day	NOAEL	Male reproductive system

Reproduction & Development Toxicity:

Acvelovir Sodium:

Duration	Species	Route	Dose	End Point	Effect (s)
Fertility	Rat	Subcutaneous	50 mg/kg/day	LOAEL	Fertility,
& Embryonic Development	Nat	Subcutaneous	50 mg/kg/day	LOAEL	Fetotoxicity,
Reproductive & Fertility	Rat	Subcutaneous	25 mg/kg/day	NOAEL	Fertility
Embryo / Fetal Development	Mouse	Oral	450 mg/kg/day	NOAEL	Not Teratogenic
Embryo / Fetal Development	Rabbit	Intravenous	50 mg/kg/day	NOAEL	Not Teratogenic
Embryo / Fetal Development	Rat	Subcutaneous	50 mg/kg/day	NOAEL	Not Teratogenic

Genetic Toxicity:

Acyclovir Sodium:

Study Type	Cell Type/Organism	Result
In Vitro Mammalian Cell Mutagenicity	Mouse Lymphoma	Positive
In Vivo Chromosome Aberration	Rat	Positive
In Vivo Chromosome Aberration	Hamster	Positive
In Vitro Cell Transformation Assay		Equivocal
Dominant Lethal Assay	Mouse	Negative

Carcinogenicity:

Acyclovir Sodium:

Version No: MSDS/Aci-AUS/DP-001 Effective Date: 1st July 2020

Duration	Species	Route	Dose	End Point	Effect (s)
2 Year(s)	Mouse	Oral	450 mg/kg/day	NOAEL	Not carcinogenic
2 Year(s)	Rat	Oral	450 mg/kg/day	NOAEL	Not carcinogenic

Carcinogen Status: None of the components of this formulation are listed as a

carcinogen by IARC, NTP or OSHA. See below.

Acyclovir Sodium IARC: Group 3 (Not Classifiable) **Hydrochloric Acid IARC:** Group 3 (Not Classifiable)

SECTION 12 - ENVIRONMENTAL IMPACT INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases

to the environment should be avoided.

SECTION 13 - DISPOSAL INFORMATION

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

SECTION 14 - TRANSPORTATION INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

SECTION 15 - REGULATORY INFORMATION

EU Symbol : Xn

EU Indication of danger : Toxic to reproduction, Category 3

: Mutagenic: Category 3

EU Risk Phrases : R62 - Possible risk of impaired fertility.

R63- Possible risk of harm to the unborn child. R68 - Possible risk of irreversible effects.

Version No: MSDS/Aci-AUS/DP-001 Effective Date: 1st July 2020

EU Risk Phrases : S22 - Do not breathe dust

S53 - Avoid exposure - obtain special instructions before use.

S36/37 - Wear suitable protective clothing and gloves.

OSHA Label: WARNING

Suspected of damaging fertility or the unborn child.

Suspected of causing genetic defects.

Canada - WHMIS: Classifications

WHMIS hazard class : Class D, Division 2, Subdivision A



Water for Injection:

Inventory - United States TSCA - Sect. 8(b) : Present Australia (AICS) : Present

REACH - Annex IV - Exemptions from the

obligations of Register: PresentEU EINECS/ELINCS List: 231-791-2

Hydrochloric Acid:

CERCLA/SARA 313 Emission reporting : 1.0 %
CERCLA/SARA Hazardous Substances and their : 5000 lb
Reportable Quantities: 2270 kg

CERCLA/SARA - Section 302 Extremely : 500 lb

Hazardous TPOs

CERCLA/SARA - Section 302 Extremely : 5000 lb

Hazardous Substances EPCRA RQs

California Proposition 65
: Not Listed Inventory - United States TSCA - Sect. 8(b)
: Present
Australia (AICS)
: Present
Standard for the Uniform Scheduling for Drugs
and Poisons
: Schedule 5
Schedule 6
EU EINECS/ELINCS List
: 231-595-7

Sodium hydroxide:

Version No: MSDS/Aci-AUS/DP-001 Effective Date: 1st July 2020

SECTION 16 - OTHER DATA

Text of R phrases mentioned in Section 3

- R62 Possible risk of impaired fertility.
- R63 Possible risk of harm to the unborn child.
- R68 Possible risks of irreversible effects

Data Sources: Publicly available toxicity information. Safety data sheets for individual ingredients.

The information in this document is believed to be correct as of the date issued. HOWEVER, NO WARRANTY OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR ANY OTHER WARRANTY IS EXPRESSED OR IS TO BE IMPLIED REGARDING THE ACCURACY OR COMPLETENESS OF THIS INFORMATION, THE RESULTS TO BE OBTAINED FROM THE USE OF THIS INFORMATION OR THE PRODUCT, THE SAFETY OF THIS PRODUCT, OR THE HAZARDS RELATED TO ITS USE. This information and product are furnished on the condition that the person receiving them shall make his own determination as to the suitability of the product for his particular purpose and on the condition that he assume the risk of his use thereof.